Opening Date of Abstract Submissions: December 1, 2017.
Abstract Submission Deadline: February 15, 2018!
Abstract submitters must register and pay their registration fees in order to submit an abstract.
Register and pay your registration fees via the online registration form.
Once you have successfully submitted and paid your registration, you will receive a link to the abstract submission page on your confirmation page and email. You may use this link at anytime.
Complete the abstract submission form and click “Finish”. The submission is a 4-step process. The abstract confirmation email will provide a username and password, allowing you to access your submission and making modifications to it until February 15, 2018.
Abstracts can be submitted in the following categories:
|Genetics & genomics|
|Biomarkers & molecular signatures|
|Pathology & disease classification|
|Predisposition & risk factors|
|Stem cells & precursor lesions|
|In vitro & in vivo models|
|Immunology & immunotherapy|
|Mechanisms of metastasis|
|Chemoresistance & recurrence|
|Survivorship & psychosocial issues|
Abstract Submission Guidelines:
- Authors are encouraged to submit only one abstract as presenting-author.
- Delegates may choose at time of submission whether they wish their abstract to be considered for oral or poster presentation. Abstracts not selected for oral presentation by the reviewers will be considered for poster presentation.
- Notifications of acceptance will be sent by the first week of April. Scheduling details and instructions for oral and poster presentations will be communicated soon after.
- Abstracts must be submitted online.
- Abstracts must be written in English.
- Abstracts must not exceed 2000 characters (with spaces) in length plus 200 characters (with spaces) for the talk title.
- The abstract must be submitted in final form. It will be published in the format it was submitted. The body of the abstract may be formatted by the submitter in the online submission form.
- Abstracts should be concise and informative and include at least preliminary data. Those stating that results will be presented or discussed may be subject to rejection.
- Non-standard abbreviations should be placed in parentheses after the full term the first time they appear.
- The use of trade names and company identification is discouraged.
- Submissions not conforming to the established guidelines may not be reviewed.